Semana da Obesidade 2020: Grande Avanço na Perda de Peso com Semaglutida? Obesity Week 2020: Great Advance in Weight Loss with Semaglutide?
Based on experience with another subcutaneous injectable GLP-1 receptor agonist, liraglutide (Saxenda, Novo Nordisk), already approved for obesity, it may be that taking chronic overweight medicine is like taking statin for high cholesterol, Wadden said.
Based on experience with another subcutaneous injectable GLP-1 receptor agonist, liraglutide (Saxenda, Novo Nordisk), already approved for obesity, it may be that taking chronic overweight medicine is like taking statin for high cholesterol, Wadden said.